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Background:Hereditary pancreatitis is caused by mutations in human cationic trypsinogen. Chymotrypsin C (CTRC) is a
proteolytic regulator of trypsinogen activation.
Results: Clinically relevant trypsinogen mutations increase autoactivation in the presence of CTRC.
Conclusion: Pathological trypsinogen activation in hereditary pancreatitis is dependent on CTRC.
Significance:Therapeutic suppression of trypsinogen autoactivation is warranted in carriers of pancreatitis-causingmutations.
Mutations in human cationic trypsinogen (PRSS1) cause
autosomal dominant hereditary pancreatitis. Increased intra-
pancreatic autoactivation of trypsinogen mutants has been
hypothesized to initiate the disease. Autoactivation of cationic
trypsinogen is proteolytically regulated by chymotrypsin C
(CTRC), which mitigates the development of trypsin activity by
promoting degradation of both trypsinogen and trypsin. Para-
doxically, CTRC also increases the rate of autoactivation by
processing the trypsinogen activation peptide to a shorter form.
The aim of this study was to investigate the effect of CTRC on
the autoactivation of clinically relevant trypsinogen mutants.
We found that in the presence of CTRC, trypsinogen mutants
associated with classic hereditary pancreatitis (N29I, N29T,
V39A, R122C, and R122H) autoactivated at increased rates and
reached markedly higher active trypsin levels compared with
wild-type cationic trypsinogen. TheA16Vmutant, known for its
variable disease penetrance, exhibited a smaller increase in
autoactivation. The mechanistic basis of increased activation
was mutation-specific and involved resistance to degradation
(N29I, N29T, V39A, R122C, and R122H) and/or increased
N-terminal processing byCTRC (A16V andN29I). These obser-
vations indicate that hereditary pancreatitis is caused by CTRC-
dependent dysregulation of cationic trypsinogen autoactiva-
tion, which results in elevated trypsin levels in the pancreas.
Hereditary chronic pancreatitis is an autosomal dominant
genetic disorder characterized by incomplete penetrance and
variable expressivity. In approximately half of the affected fam-
ilies, the disease is caused by heterozygous mutations in the
PRSS1 (protease, serine, 1) gene, which encodes human cati-
onic trypsinogen (1–4). The human pancreas secretes three
isoforms of trypsinogen, and the cationic isoform contributes
about two-thirds of the trypsinogen content in the pancreatic
juice. In the large majority of hereditary pancreatitis families
worldwide, the causative mutation is either R122H (70%) or
N29I (20%). Less frequently, the same amino acid positions
are altered by mutations R122C (3%) and N29T (1%),
respectively. In addition, a large number of rare PRSS1 muta-
tions have been identified not only in kindreds with hereditary
pancreatitis but also in patients with sporadic idiopathic pan-
creatitis. Many of these most likely represent harmless variants
or mutations with variable or low disease penetrance (5).
Functional studies using recombinant cationic trypsinogen
mutants demonstrated thatmutationsN29I, N29T, and R122H
increased autoactivation (trypsin-mediated trypsinogen activa-
tion), albeit to a modest degree (6–8). Convincing evidence
that increased autoactivation is an important mechanism in
hereditary pancreatitis came from studies on a subset of rare
mutations (D22G, K23R, and K23I_I24insIDK) that affect the
trypsinogen activation peptide and cause a dramatic increase in
autoactivation (9–11). However, activation peptide mutations
did not seem to cause more severe disease, and the apparent
lack of correlation between biochemical and clinical pheno-
types associated with different trypsinogen mutations re-
mained puzzling. An early study found that mutation R122C
caused loss of function due to misfolding; however, this proved
to be an artifact of the in vitro refolding procedure used at the
time (12). On the other hand, mutant R116C, another cysteine
mutant associated with hereditary pancreatitis, was shown to
misfold and elicit endoplasmic reticulum stress in HEK293T
cells, suggesting that mutation-induced misfolding and conse-
quent endoplasmic reticulum stress may be an alternative dis-
ease mechanism, unrelated to trypsinogen activation (13).
Whether or not mutant R116C misfolds in acinar cells is still
uncertain, and the role of endoplasmic reticulum stress in pan-
creatitis, although intensely researched, remains speculative.
A number of recent studies from our laboratory demon-
strated that cationic trypsinogen and trypsin are under the reg-
ulation of chymotrypsin C (CTRC)2 in humans. First, we found
that CTRC stimulates autoactivation of cationic trypsinogen by* Thisworkwas supported, inwholeor inpart, byNational Institutes ofHealth
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processing the trypsinogen activation peptide to a shorter form,
which is more readily cleaved by trypsin (14). The A16V cati-
onic trypsinogen mutation, which changes the N-terminal res-
idue of the activation peptide, increases the rate of N-terminal
processing by CTRC. Subsequently, we found that CTRC pro-
motes degradation of cationic trypsin by a mechanism that
involves cleavage of the Leu-81–Glu-82 peptide bond in the
calcium-binding loop and an autolytic cleavage by trypsin at the
Arg-122–Val-123 peptide bond (15). Both cleavages are
required, andmutation of either Leu-81 or Arg-122 blocks deg-
radation. CTRC-mediated cleavage at Leu-81 is calcium-de-
pendent, and millimolar concentrations of calcium protect
trypsin against degradation. Finally, we and others obtained
genetic evidence that loss-of-function variants of CTRC
increase the risk for chronic pancreatitis in humans, indicating
that CTRC plays an important protective role in the pancreas
against premature trypsinogen activation (16–18). The CTRC-
mediated effects on trypsinogen and trypsin are highly specific,
and other chymotrypsin or elastase isoforms have no such
activity.
We also observed that CTRC degrades cationic trypsinogen
at a faster rate than cationic trypsin (15), suggesting that CTRC
might regulate mainly the activation of trypsinogen to trypsin
rather than controlling active trypsin levels through degrada-
tion. Autoactivation of cationic trypsinogen and its hereditary
pancreatitis-associated mutants has never been studied in the
presence of CTRC. In this study, we therefore undertook these
experiments based on the hypothesis that pancreatitis-associ-
atedmutantsmay exert their effect in aCTRC-dependentman-
ner. The findings reveal a prominent biochemical phenotype
shared by all disease-causing mutants that involves altered reg-
ulation by CTRC and, as a consequence, strongly increased
trypsinogen activation in the presence of CTRC.
EXPERIMENTAL PROCEDURES
Nomenclature—Amino acid residues in human cationic
trypsinogen (PRSS1) are numbered starting with the initiator
methionine of the primary translation product according to the
recommendations of the Human Genome Variation Society.
Expression Plasmids and Mutagenesis—Construction of the
pTrapT7-intein-Hu1, pTrapT7-Hu1-K23Q, and pcDNA3.1()-
Hu1 expression plasmids harboring the coding sequence for
human cationic trypsinogen (Hu1) was reported previously (6,
7, 19, 20). In an earlier publication,mutationK23Qwas denoted
asK15Q, using the conventional chymotrypsin numbering (20).
In the pTrapT7-intein-Hu1 plasmid, the native N terminus of
human cationic trypsinogen (Ala-Pro-Phe) is fused to the C
terminus of a mini-intein (19). In the pTrapT7-Hu1-K23Q
plasmid, the N-terminal sequence of trypsinogen was changed
to Met-Ala-Phe-Pro-Val due to cloning manipulations (20).
Mutations were introduced using overlap-extension PCR
mutagenesis andwere verified byDNA sequencing of the entire
gene.
Expression, Purification, and Activation of Human CTRC—
Construction of the pcDNA3.1()-CTRC expression plasmid
was reported previously (15). In this study, a His10 affinity tag
was engineered onto the C terminus of the protein. CTRC was
expressed in HEK293T cells with transient transfection as
described (21). Approximately 900 ml of conditioned medium
was used for purification on a nickel-nitrilotriacetic acid Super-
flow cartridge (Qiagen) equilibratedwith BufferNPI-20 (50mM
NaH2PO4, 300 mM NaCl, and 20 mM imidazole (pH 8.0)). The
medium was loaded onto the column at a flow rate of 4 ml/min
using a loading pump, and the column was washed with Buffer
NPI-20 until the absorbance at 280 nm returned to the base
line. CTRC was eluted with Buffer NPI-250 (50 mM NaH2PO4,
300 mM NaCl, and 250 mM imidazole (pH 8.0)) at a flow rate of
2 ml/min, and 5-ml fractions were collected. Aliquots (100 l)
of the fractions were analyzed by 15% SDS-PAGE and Coomas-
sie Blue staining, and peak fractions were pooled and dialyzed
for 24 h against two changes of 3.5 liters of 50 mM NaH2PO4
buffer (pH 8.0) containing 300 mM NaCl. The dialyzed CTRC
proenzyme solution was concentrated using a Vivaspin con-
centrator (10-kDamolecular mass cutoff). CTRC zymogen was
activated with human cationic trypsin, and CTRC concentra-
tions were determined by active site titration with ecotin as
described previously (22). The final working CTRC stock solu-
tion was diluted to 500 nM in 0.1 M Tris-HCl (pH 8.0) and 0.05%
Tween 20.
Expression and Purification of Human Cationic Trypsinogen—
Wild-type and mutant trypsinogens were expressed as intein
fusion proteins in aminopeptidase P-deficient Escherichia coli
strain LG-3 as described previously (19, 23). After spontaneous
self-cleavage, the fusion protein gave rise to cationic trypsino-
gen with a homogeneous authentic N-terminal sequence.
K23Q trypsinogen mutants were expressed in E. coli
BL21(DE3) cells, with the exception of the A16V/K23Q double
mutant, which was made as an intein fusion and expressed in
strain LG-3. Trypsinogen was solubilized from the inclusion
bodies, refolded in vitro, and purified by ecotin affinity chroma-
tography according to published protocols (6, 7, 19, 23, 24).
Mutant R122C, which is prone to misfolding in vitro (12), was
expressed in HEK293T cells by transient transfection. The
growthmedium contained 1 mM benzamidine to prevent auto-
activation. Trypsinogen was purified from 400 ml of condi-
tionedmediumby ecotin chromatography. The concentrations
of trypsinogen preparations were calculated from their UV
absorbance at 280 nm using an extinction coefficient of 37,525
M1 cm1.
Trypsin Activity Assay—Trypsin activity wasmeasured in 0.1
M Tris-HCl (pH 8.0) containing 1 mM CaCl2 and 0.05% Tween
20 using the chromogenic trypsin substrate N-benzyloxycar-
bonyl-Gly-Pro-Arg p-nitroanilide at a final concentration of
0.15 mM in a final volume of 200 l at 22 °C. Typically, a 2-l
sample was mixed with 48 l of assay buffer, and the reaction
was started by the addition of 150 l of substrate dissolved in
the same buffer. The release of the yellow p-nitroaniline was
followed for 1 min at 405 nm in a SpectraMax Plus384 micro-
plate reader (Molecular Devices).
Gel Electrophoresis and Densitometry—Trypsinogen sam-
ples were precipitated with trichloroacetic acid (10% final con-
centration), and the precipitate was recovered by centrifuga-
tion, dissolved in 20 l of Laemmli sample buffer containing
100 mM dithiothreitol (final concentration), and heat-dena-
tured at 95 °C for 5 min. Electrophoretic separation was per-
formed on 15% SDS-polyacrylamidemini gels in standard Tris/
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glycine buffer. Gels were stained for 30 min with 0.5% Brilliant
Blue R-250 dissolved in 40% methanol and 10% acetic acid and
destained overnight with 30% methanol and 10% acetic acid.
Gels were dried between two layers of cellophane and scanned
at a resolution of 300 dots/inch in grayscalemode.Quantitation
of bands was carried out with the Quantity One 4.6.9 software
(Bio-Rad). Rectangleswere drawn around each band of interest,
and an identical rectangle was used in each lane for background
subtraction.
RESULTS
CTRC Regulates Autoactivation of Cationic Trypsinogen
Human cationic trypsinogen exhibits an unusually high pro-
pensity for autoactivation relative to other mammalian
trypsinogens studied so far (25). When trypsinogen at 1 M
concentration was incubated with 10 nM trypsin at 37 °C at pH
8.0 in the presence of 1 mM Ca2, conversion to trypsin was
essentially complete within 40min (Fig. 1A), and the final tryp-
sin activity remained stable. The addition of low concentrations
(1–25 nM) of humanCTRC to this reaction resulted in a slightly
increased rate of autoactivation, with reduced final trypsin lev-
els that were inversely proportional to the CTRC concentration
present and that slowly decreased over time from their peak
value (Fig. 1A). The small increase in the rate of autoactivation
was due toN-terminal processing byCTRC (14); suppression of
the final trypsin levels was caused by CTRC-mediated trypsin-
ogen degradation, and the slow decrease in trypsin activity was
due to trypsin degradation by CTRC (15). Previously, we deter-
mined that CTRC-dependent trypsin degradation involves
cleavages at Leu-81 (by CTRC) and Arg-122 (by trypsin) (15).
To confirm that the same cleavages are required for trypsino-
gen degradation during autoactivation in the presence of
CTRC,mutants L81A andR122Awere studied (Fig. 1,B andC).
In the absence of CTRC, autoactivation of mutant L81A was
identical to that of the wild type, whereas mutant R122A
showed a small increase in the rate (cf. Fig. 1, A–C). Thus, as
expected, these mutations had no major impact on autoactiva-
tion per se. In contrast, when assayed in the presence of 5 or 25
nM CTRC, both mutations protected against CTRC-induced
trypsinogen degradation and resulted in rapid autoactivation to
high trypsin levels (Fig. 1, B andC).Mutant L81A autoactivated
to the same trypsin levels with or without CTRC (Fig. 1B),
whereas mutant R122A showed only a small CTRC-dependent
decrease in the final trypsin activity (Fig. 1C). Furthermore, due
to the lack of degradation, the effect of CTRC-mediated N-ter-
minal processing became much more apparent, i.e. the rates of
autoactivation were noticeably increased. These results indicate
that CTRC regulates autoactivation of human cationic trypsino-
gen, and mutations that interfere with these processes can have
profound effects on trypsin levels resulting from trypsinogen acti-
vation. Consequently, we hypothesized that naturally occurring
hereditary pancreatitis-associated cationic trypsinogenmutations
might exert their effect through this mechanism.
Autoactivation of Cationic TrypsinogenMutants in Presence of
CTRC
Mutations of Arg-122 (R122C and R122H) are the clinically
most frequent pancreatitis-causing genetic variants. Because
bothmutations block the trypsin-mediated cleavage of theArg-
122–Val-123 peptide bond, CTRC-dependent trypsinogen
degradation should be impaired, resulting in increased autoac-
tivation in a manner that was already observed with the R122A
non-natural mutation in Fig. 1C. Because mutant R122C tends
tomisfold during the in vitro refolding procedure used (12), this
mutant was expressed in transiently transfectedHEK293T cells
and purified from the conditioned medium. As an appropriate
control, a wild-type cationic trypsinogen preparation was also
produced by the same method. When tested in the absence of
CTRC, both mutations R122C and R122H increased the rate of
FIGURE 1. Effect of CTRC on autoactivation of human wild-type cationic
trypsinogen (A) and mutants L81A (B) and R122A (C). Wild-type and
mutant trypsinogenswere incubated at 1Mwith 10 nM initial trypsin in 0.1 M
Tris-HCl (pH8.0), 1mMCaCl2, and0.05%Tween20 (final concentrations) in the
absence or presence of the indicated CTRC concentrations at 37 °C. At given
times, 2-l aliquots were removed, and trypsin activity was measured as
described under “Experimental Procedures.” Trypsin activity is expressed as a
percentage of the maximal activity in the absence of CTRC. Representative
experiments from two replicates are shown.
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autoactivation of cationic trypsinogen to a modest extent, 1.2-
and 1.5-fold, respectively (Fig. 2A). In contrast, autoactivation
ofmutants R122C andR122Hwas dramatically increased in the
presence of CTRC relative to the wild type (Fig. 2, B and C).
Trypsin levels remained stable over the time course studied,
consistent with previous observations that trypsin mutants
R122C and R122H are resistant to degradation by CTRC (15).
In the absence of CTRC, rates of autoactivation can be esti-
mated assuming that the reaction proceeds as “trypsinogen 
trypsin 2 trypsin” and degradation is negligible, but the same
formula cannot be used to describe autoactivation in a quanti-
tative manner once CTRC is present in the system. From a
biological perspective, the peak trypsin value and the time to
reach the maximal amplitude seem intuitively important.
Therefore, we compared the area under the curve between the
wild type and mutants from time 0 until the time the wild type
reached its peak trypsin activity.We found thatmutants R122C
andR122H showed3.3- and 3.5-fold higher values, respectively,
compared with wild type in the presence of 5 nM CTRC, and
these values increased to 5.0- and 4.8-fold, respectively, in the
presence of 25 nM CTRC. The dependence of these values on
the CTRC concentration suggests that the differences between
wild-type and mutant trypsinogens may be even larger under
physiological conditions, where CTRC concentrations are
higher than used experimentally (see “Discussion”).
Mutations of Asn-29 (N29I and N29T) are the second most
prevalent hereditary pancreatitis-associated changes in cati-
onic trypsinogen. In the absence of CTRC, mutation N29I
slightly (1.5-fold) increased the rate of autoactivation, whereas
mutation N29T had a somewhat more pronounced (2.5-fold)
stimulating effect (Fig. 2A). In the presence ofCTRC, compared
with wild-type trypsinogen, autoactivation was strongly accel-
erated by both mutations, resulting in remarkably higher tryp-
sin levels (Fig. 2,B andC). For theN29Imutant, the values of the
area under the curve were 4.1-fold higher than those for the
wild type in the presence of both CTRC concentrations tested.
For the N29T mutant, the same values were 3.7- and 5.2-fold
higher compared with the wild type at 5 and 25 nM CTRC,
respectively. In contrast to mutants R122C and R122H, trypsin
mutants N29I and N29T were prone to degradation by CTRC,
and trypsin levels steadily decreased over time. Interestingly,
trypsin degradation showed mutation-specific differences,
as trypsin mutant N29I was more readily degraded by CTRC
than trypsinmutant N29T, which had superior stability, partic-
ularly at higher CTRC concentrations (Fig. 2C).
The results presented in Fig. 2 indicate that mutations asso-
ciated with classic autosomal dominant hereditary pancreatitis
exhibit a similar biochemical phenotype in the presence of
CTRC that is characterized by increased rates of trypsinogen
activationwith high levels of trypsin generated. To extend these
studies, we tested the effect of mutation V39A on trypsinogen
autoactivation. This mutation was described in a single hered-
itary pancreatitis family in Italy, where it showed convincing
segregation with the disease in seven family members (26). In
the absence of CTRC, the V39A mutation had no significant
effect on trypsinogen autoactivation, whereas in the presence of
CTRC, a large increase in autoactivation was observed com-
pared with wild-type cationic trypsinogen (Fig. 3). Mutant
V39A autoactivated at a slower rate than mutant R122H, and
final trypsin levels approached but remained lower than those
seen with mutant R122H. The values of the area under the
curve were 2.1- and 2.7-fold higher compared with wild type in
the presence of 5 and 25 nM CTRC, respectively (cf. mutant
R122H, 2.9- and 4.7-fold in the same experiment). These quan-
titative differences notwithstanding, mutant V39A exhibited a
FIGURE2.Autoactivationofpancreatitis-associated cationic trypsinogen
mutants N29I, N29T, R122C, and R122H in presence of CTRC. Wild-type
andmutant trypsinogens were incubated at 1Mwith 10 nM initial trypsin in
0.1MTris-HCl (pH8.0), 1mMCaCl2, and0.05%Tween20at 37 °C in theabsence
(A) or presence of CTRC at 5 nM (B) or 25 nM (C) (final concentrations). At the
indicated times, 2-l aliquots were removed, and trypsin activity was meas-
ured as described under “Experimental Procedures.” Trypsin activity is
expressed as a percentage of the maximal activity in the absence of CTRC.
Representative experiments from two or three replicates are shown.
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biochemical phenotype similar to themore frequent pancreati-
tis-associated mutations.
Mutation A16V is associated with variable disease pen-
etrance and was identified not only in hereditary pancreatitis
families but also in sporadic cases with no family history, sug-
gesting aweaker biochemical phenotype (27, 28). Themutation
is found in3% of PRSS1mutation-positive pancreatitis cases,
although a recent study from Denmark reported higher
regional occurrence (29). The A16Vmutation alters the N-ter-
minal amino acid residue of the trypsinogen activation peptide.
Amino acid 16 is the first residue of mature trypsinogen, as the
secretory signal peptide (amino acids 1–15) is cleaved off dur-
ing endoplasmic reticulum entry. Because the activation pep-
tide is released during the activation process, mutation A16V is
not present in active trypsin and thus cannot alter trypsin
function. Previously, we demonstrated that mutation A16V
increased the N-terminal processing of the trypsinogen activa-
tion peptide by CTRC at the Phe-18–Asp-19 peptide bond by
4-fold, which is expected to result in increased autoactivation
(14). Here, we found that in the absence of CTRC, mutation
A16V had no effect on trypsinogen autoactivation (Fig. 3A), as
demonstrated previously (19). In the presence of CTRC, the
rate of autoactivation was increased measurably relative to the
wild type, albeit to a lesser degree than observedwith the highly
disease penetrant mutations (Fig. 3, B and C). The values of the
area under the curve were 1.8- and 2.0-fold higher compared
with thewild type in the presence of 5 and 25 nMCTRC, respec-
tively. Thus, the variable clinical presentation of the A16V
mutation is consistent with its milder biochemical phenotype.
Mechanistic Basis of Increased Autoactivation in Presence of
CTRC
The results presented above indicate that proteolytic regula-
tion of cationic trypsinogenmutants byCTRC is altered in such
a manner that results in more robust trypsinogen activation. In
theory, trypsinogen mutations can cause increased autoactiva-
tion by at least four different mechanisms: increased trypsin-
mediated cleavage of the activation peptide caused either (i)
directly by a mutational effect or (ii) indirectly by increased
N-terminal processing at the Phe-18–Asp-19 peptide bond by
CTRC; or impaired trypsinogen degradation during autoacti-
vation due to (iii) slower cleavage of the Leu-81–Glu-82 peptide
bond by CTRC or (iv) decreased cleavage of the Arg-122–Val-
123 peptide bond by trypsin. In the following experiments,
these potential mechanisms were explored.
Mechanism i—As presented in Figs. 2A and 3A and reported
previously (6, 7, 19), most mutations studied here had little
direct effect on autoactivation. Mutations R122H and N29I
increased the rate of autoactivation by 1.5-fold, and mutation
R122C by 1.2-fold. Mutations A16V and V39A had nomeasur-
able stimulating effect. The only exceptionwasmutationN29T,
which increased the rate of autoactivation by2.5-fold.
Mechanism ii—N-terminal processing of cationic trypsino-
gen by CTRC removes the three N-terminal amino acid resi-
dues from the activation peptide, which results in a small but
detectable shift on SDS-polyacrylamide gels run under nonre-
ducing conditions. Using this assay, we previously found that
mutations A16V and N29I increased CTRC-mediated N-ter-
minal processing of cationic trypsinogen by 4- and 1.4-fold,
respectively (14). In our current experiments, we confirmed
these findings and found even stronger effects after densito-
metric analysis (Fig. 4). Thus,mutationA16V increased the rate
of N-terminal processing by 5.8-fold relative to the wild type,
and mutation N29I by 2.6-fold. On the other hand, mutations
FIGURE3.Autoactivationofpancreatitis-associated cationic trypsinogen
mutants A16V and V39A in presence of CTRC. For comparison, mutant
R122H was also included. Wild-type and mutant trypsinogens were incu-
bated at 1 M with 10 nM initial trypsin in 0.1 M Tris-HCl (pH 8.0), 1 mM CaCl2,
and0.05%Tween20 at 37 °C in the absence (A) or presenceof CTRCat 5nM (B)
or 25 nM (C) (final concentrations). At the indicated times, 2-l aliquots were
removed, and trypsin activity wasmeasured as described under “Experimen-
tal Procedures.” Trypsin activity is expressed as a percentage of the maximal
activity in the absence of CTRC. Representative experiments from two repli-
cates are shown.
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V39A, R122C, and R122H had no appreciable effect on this
CTRC activity. Interestingly, mutant N29T was processed
slightly (1.3-fold) slower than wild-type trypsinogen (Fig. 4).
Mechanism iii—CTRC-mediated degradation of cationic
trypsinogen is initiated by cleavage of the Leu-81–Glu-82 pep-
tide bond in the calcium-binding loop (15). This cleavage is
rapid when the binding loop is unoccupied, whereas calcium
binding inhibits cleavage (KD 20 M), with complete inhibi-
tion requiring 10mMor higher concentrations. Experimentally,
the reaction is best followed in the absence of calciumwhen full
time courses of degradation can bemeasured using SDS-PAGE
and densitometry. Fig. 5 demonstrates that the rate of cleavage
by CTRC at Leu-81 became measurably reduced in mutants
N29I (2.5-fold), N29T (3.6-fold), V39A (1.5-fold), R122C (2.1-
fold), and R122H (3.1-fold), whereas it was essentially
unchanged in mutant A16V.
Mechanism iv—Trypsin-mediated cleavage of the Arg-122–
Val-123 peptide bond is required forCTRC-dependent trypsin-
ogen degradation (15). Cleavage of this peptide bond by trypsin
does not proceed to completion, but due to trypsin-mediated
peptide bond resynthesis, a dynamic equilibrium is reached
between the uncleaved and cleaved trypsinogen forms (20). To
FIGURE4.N-terminal processingofhumancationic trypsinogenandpan-
creatitis-associatedmutants by CTRC.Wild-type andmutant trypsinogens
were incubated at 2Mwith 25 nMCTRC in 0.1 M Tris-HCl (pH 8.0), 1mMCaCl2,
and 20 nM SPINK1 trypsin inhibitor (final concentrations) at 37 °C. The trypsin
inhibitor was included to prevent autoactivation. A, at the indicated times,
reactions were terminated by precipitation with 10% trichloroacetic acid
(final concentration), and samples were analyzed by 15% nonreducing SDS-
PAGE andCoomassie Blue staining. Relevant segments of representative gels
from two replicates demonstrate the small mobility shift of the trypsinogen
band caused by N-terminal processing. B, densitometric analysis of stained
gels showing the changes in the intensity of the unprocessed intact trypsin-
ogen band as a percentage of the total intensity of the processed and unpro-
cessed bands. Rates of processing were calculated from linear fits to semi-
logarithmic plots. Error bars were omitted for clarity. The S.E. was within 10%
of the mean.
FIGURE 5. Cleavage of Leu-81–Glu-82 peptide bond in human cationic
trypsinogenandpancreatitis-associatedmutantsbyCTRC.Wild-typeand
mutant trypsinogenswere incubatedat 2Mwith25nMCTRC in0.1MTris-HCl
(pH 8.0) and 20 nM SPINK1 trypsin inhibitor (final concentrations) at 37 °C. The
trypsin inhibitor was included to prevent autoactivation. A, at the indicated
times, reactions were terminated by precipitation with 10% trichloroacetic
acid (final concentration), and samples were analyzed by 15% reducing SDS-
PAGE and Coomassie Blue staining. The asterisk indicates the faint band
migrating at5 kDa, which is the product of a secondary cleavage at Leu-41
by CTRC. Representative gels of two or more experiments are shown. B, den-
sitometric analysis of stained gels showing the changes in the intensity of the
unprocessed intact trypsinogen band. Rates of degradation were calculated
from linear fits to semilogarithmic plots. Error bars were omitted for clarity.
The S.E. was within 12% of the mean.
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investigate the effect of pancreatitis-associated mutations on
the ability of trypsin to cleave trypsinogen at Arg-122, we used
a stable non-activable trypsinogen in which the activating site
was mutated (K23Q) (20). Mutations were transferred to the
K23Q background, and trypsinogen at 2 M concentration was
digested with 10 nM trypsin in the presence of low calcium
concentrations (5 M), which favor cleavage. Time courses of
digestion were analyzed by SDS-PAGE and densitometry (Fig.
6). Because the two products of the cleavage reaction co-mi-
grated as a single band, measurement of the hydrolysis equilib-
rium between intact and cleaved trypsinogens was straightfor-
ward. The equilibrium mixture of wild-type trypsinogen
contained 35% intact and 65% cleaved forms. Not surprisingly,
mutations R122H and R122C (data not shown) completely
blocked cleavage at Arg-122. Mutations N29I and N29T
slightly (1.2- and 1.3-fold, respectively) decreased the rate of
cleavage and increased the equilibrium levels of uncleaved tryp-
sinogen to 40 and 45%, respectively. Remarkably, mutation
V39A decreased the rate of cleavage by at least 3-fold and
shifted the cleavage equilibrium toward the uncleaved form
(50%). Finally, as expected, mutation A16V had no effect on
this reaction (data not shown). Taken together, it appears that
the mechanistic basis of increased trypsinogen autoactivation
in the presence of CTRC ismutation-specific andmay involve a
combination of relatively smaller effects, as summarized in
Table 1.
Effect of Pancreatitis-associatedMutations on Trypsin
Stability
Historically, the biochemical effects of pancreatitis-associ-
ated trypsinogen mutations used to be interpreted in the con-
text of trypsin stability (1). In light of the present and other
recent data, the primary effects of trypsinogen mutations
should be considered in terms of trypsinogen autoactivation.
Nonetheless, final trypsin levels achieved during trypsinogen
autoactivation are also influenced by trypsin stability to a lesser
degree. As shown in Fig. 1A, peak trypsin levels slowly declined
due to CTRC-mediated trypsin degradation, and mutations
N29T, R122C, and R122H seemed to render trypsin more
resistant to CTRC-mediated degradation, as indicated by the
sustained trypsin plateau phase in Fig. 2 (B andC). To compare
the effect of pancreatitis-associated mutations on trypsin deg-
radation in amore quantitative manner, we activated wild-type
and mutant trypsinogens with human enteropeptidase and fol-
lowed the loss of trypsin activity after the addition of 25 nM
CTRC.We performed these experiments in the presence of low
calciumconcentrations (5M) to allow the reactions to proceed
at a higher rate. Fig. 7 demonstrates that, relative to wild-type
trypsin, inactivation of trypsinmutants R122C and R122H pro-
ceeded at 11-fold slower rates. Mutants N29T and V39A were
degraded 3-fold slower than wild-type trypsin, whereas deg-
radation of mutant N29I was comparable with the wild type
(see also Table 1). Note that mutation A16V had no effect on
trypsin stability, as thismutation is not present in active trypsin.
DISCUSSION
In this study, we have demonstrated that cationic trypsino-
gen mutations that are associated with classic autosomal dom-
FIGURE 6. Cleavage of Arg-122–Val-123 peptide bond in human cationic
trypsinogen and pancreatitis-associated mutants by cationic trypsin.
Wild-type and mutant trypsinogens were incubated at 2 M with 10 nM
human cationic trypsin in 0.1 M Tris-HCl (pH 8.0) and 5MCaCl2 (final concen-
trations) at 37 °C. All trypsinogens contained the K23Q mutation to prevent
autoactivation. A, at the indicated times, reactions were terminated by pre-
cipitation with 10% trichloroacetic acid (final concentration), and samples
were analyzed by 15% reducing SDS-PAGE and Coomassie Blue staining.
Note that the two cleavage fragments co-migrated and appeared as a single
band at15 kDa. Representative gels of two experiments are shown. B, den-
sitometric analysis of stained gels showing the changes in the intensity of the
uncleaved intact trypsinogen band as a percentage of the total intensity of
the cleaved (Tg*) and uncleaved (Tg) bands. Error bars were omitted for clar-
ity. The S.E. was within 10% of the mean.
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inant hereditary pancreatitis all exhibit markedly increased
autoactivation in the presence of CTRC. These findings mark
the successful conclusion of a more than decade-long quest for
the common biochemical defect caused by hereditary pancre-
atitis-associated mutations. Increased autoactivation was pro-
posed as a unifying mechanism as early as 2000; however, the
clinically common mutations N29I and R122H had a relatively
minor, not particularly convincing effect (7) (also see Fig. 2A).
Even more confusing was the observation that activation pep-
tide mutations D22G, K23R, and K23I_I24insIDK stimulated
autoactivation in a dramatic manner yet still caused essentially
the same clinical disease as mutations N29I and R122H (9–11).
Thus, there appeared to be no correlation between the bio-
chemical phenotype and the biological effect. The results pre-
sented here resolve this apparent contradiction and clearly
demonstrate a very similar biochemical phenotype for the
highly penetrant, hereditary pancreatitis-associated mutations
N29I, N29T, V39A, R122C, and R122H. Furthermore, consist-
ent with its variable disease penetrance, mutant A16V was
shown to exhibit a smaller increase in autoactivation than
mutants causing hereditary pancreatitis.
Unexpectedly, investigations into the mechanistic basis of
increased autoactivation revealed several mutation-specific
mechanisms, often acting in concert (see Table 1). (i) Even in
the absence of CTRC, mutations N29I, N29T, R122C, and
R122H had a direct stimulatory effect on the rate of autoactiva-
tion, which ranged from 1.2- to 2.5-fold. These relatively small
effects represent increased proteolytic accessibility of the acti-
vation peptide caused by the mutations. (ii) Mutations A16V
and N29I increased the rate of N-terminal processing of the
trypsinogen activation peptide by CTRC by 5.8- and 2.6-fold,
respectively. N-terminal processing stimulates trypsin-medi-
ated cleavage of the activation peptide (i.e. autoactivation) by
relieving an electrostatic inhibitory interaction between the tet-
ra-aspartate motif in the activation peptide and Asp-218 on
trypsin (14). Notably, this is the only biochemical change
caused by mutation A16V. (iii) CTRC-dependent degradation
of cationic trypsinogen requires cleavages at Leu-81 by CTRC
and at Arg-122 by trypsin. With the exception of A16V, all
mutations affected both of these cleavages. With respect to
cleavage at Leu-81 by CTRC, mutations N29I, N29T, V39A,
R122C, and R122H all had a modest inhibitory effect that
ranged from 1.5- to 3.6-fold. (iv) With respect to the autolytic
cleavage at Arg-122, mutations R122C and R122H blocked this
reaction, whereas mutation V39A decreased the rate of cleav-
age by 3-fold. Mutations N29I and N29T also had a small but
measurable negative effect on the rate of cleavage. Further-
more, all mutations shifted the cleavage equilibrium toward
uncleaved trypsinogen to various degrees. The altered cleavage
at Arg-122 seemed to be the dominant functional effect for
mutations R122C, R122H, and possibly V39A. As summarized
in Table 1, the synergistic action of these four mechanisms is
best seen with mutant N29I, where all four mechanisms
increase autoactivation to a relatively small extent, but their
cumulative effect becomes striking (see Fig. 2B). Three of the
fourmechanisms are operational inmutantsN29T, R122C, and
R122H and two in mutant V39A (Table 1). As pointed out
above, the only exception ismutantA16V,where a singlemech-
anism is responsible for the disease-associated phenotype of
increased autoactivation. Finally, fourmutations (N29T, V39A,
R122C, and R122H) also reduced CTRC-mediated trypsin deg-
radation, which may also contribute to the peak trypsin levels
achieved during autoactivation. However, one of the key mes-
sages of this study is that the pathogenic effects of pancreatitis-
associated trypsinogen mutations should be interpreted, first
and foremost, in the context of trypsinogen autoactivation and
not trypsin stability, as suggested earlier (1).
The structural basis for the decreased cleavage at Leu-81 by
CTRC and at Arg-122 by trypsin in the trypsinogen mutants is
not readily apparent, but available crystal structures may give
some clues. In the bovine trypsinogen x-ray structures (Protein
Data Bank codes 2TGD and 1TGN), the side chains of Arg-122
(Arg-117 in chymotrypsin numbering), Asn-84 (Asn-79 in chy-
motrypsin numbering), and Asn-33 (Asn-25 in chymotrypsin
TABLE 1
Mechanistic basis of increased autoactivation of pancreatitis-associated human cationic trypsinogenmutants
Changes that result in increased autoactivation in the presence of CTRC are shown in boldface. See “Results” for details.
Mutation
Autoactivation
without CTRC
Trypsinogen processing at
Phe-18 by CTRC
Trypsinogen cleavage at
Arg-122 by trypsin
Trypsinogen cleavage at
Leu-81 by CTRC
Trypsin degradation
by CTRC
A16V Unchanged Increased 5.8-fold Unchanged Unchanged Unchanged
N29I Increased 1.5-fold Increased 2.6-fold Decreased 1.2-fold Decreased 2.5-fold Unchanged
N29T Increased 2.5-fold Decreased 1.3-fold Decreased 1.3-fold Decreased 3.6-fold Decreased 3.3-fold
V39A Unchanged Unchanged Decreased 3-fold Decreased 1.5-fold Decreased 2.9-fold
R122C Increased 1.2-fold Unchanged Blocked Decreased 2.1-fold Decreased 11-fold
R122H Increased 1.5-fold Unchanged Blocked Decreased 3.1-fold Decreased 11-fold
FIGURE 7. Inactivation of human cationic trypsin andpancreatitis-associ-
ated mutants by CTRC. Wild-type and mutant trypsinogens at 1 M were
activated to trypsin with 7 ng/ml (64 pM) human enteropeptidase in 0.1 M
Tris-HCl (pH 8.0), 5 M CaCl2, and 0.05% Tween 20 for 30 min at 37 °C (final
concentrations). Initial trypsin activitywas determined, and incubationswere
continued at 37 °C in the absence or presence of 25 nM CTRC. Loss of trypsin
activity was followed by withdrawing 2-l aliquots and measuring trypsin
activity as described under “Experimental Procedures.” Trypsin activity is
expressed as a percentage of the initial activity. Rates of trypsin inactivation
were calculated from linear fits to semilogarithmic plots. Data points repre-
sent the average of two or three experiments. Error bars were omitted for
clarity. The S.E. was within 10% of the mean.
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numbering) are within “striking distance” (4Å or less) of each
other, suggesting that subtle structural changes altering these
interactionsmay influence cleavage at Arg-122 (Fig. 8). Because
Leu-81 in human cationic trypsinogen lies in proximity to Asn-
84, the same mechanism may account for altered cleavage at
Leu-81. Mutations N29I, N29T, and possibly V39A may affect
Asn-33, whereas mutations R122C and R122Hmay affect both
Asn-33 and Asn-84.
The disease-relevant compartment in the pancreas where
increased trypsinogen activationmight take place in hereditary
pancreatitis is unknown, but the pancreatic juice within the
excretory ducts seems to be the best candidate. This notion is
supported by the observations that mutations in the cystic
fibrosis transmembrane conductance regulator, expressed in
duct epithelia, or anatomical variations in duct morphology
increase the risk for chronic pancreatitis (30). The autoactiva-
tion experiments presented here were performed in the pres-
ence of 1 mM CaCl2. In human pancreatic juice, total calcium
concentrations between 0.2 and 0.9 mM were reported, with
higher values found in patients with chronic pancreatitis (31–
33). One study reported ionized calcium concentrations at 0.3
mM, with 0.6 mM total calcium (32). We chose to use 1 mM
calcium in our experiments because, under these conditions,
trypsinogen autoactivation is easy tomeasure with high trypsin
signal even in the presence of CTRC. At slightly lower calcium
concentrations that may prevail in the pancreatic juice, autoac-
tivation reactions would proceed with similar kinetics but with
a smaller amplitude. Another important factor to consider is
the CTRC concentrations used. CTRC is secreted in a zymogen
form (chymotrypsinogenC) to the pancreatic juice at levels that
are 20-fold lower than those of cationic trypsinogen as esti-
mated by immunoblotting using purified proenzymes as stand-
ards.3 CTRC has to be activated by trypsin, and this activating
cleavage reaction is at least 100-fold faster than trypsin-medi-
ated trypsinogen activation.4 Consequently, small amounts of
trypsin generated in the pancreatic juice can preferentially acti-
vate CTRC before trypsinogen autoactivation would progress.
We performed our experiments at lower CTRC-to-trypsinogen
ratios (1:200 and 1:80) than one would expect to find during
premature trypsinogen activation in the pancreas. It is likely
that in normal pancreatic juice, CTRC-dependent protection
against premature autoactivation is more effective and devel-
opment of trypsin activity is much more dampened than indi-
cated in our autoactivation figures. Under these conditions, the
higher autoactivation of mutant trypsinogens seen in our
experiments would manifest as increased likelihood of appear-
ance of trypsin activity. Such a scenario is consistent with the
clinical course of hereditary pancreatitis, which involves recur-
rent acute attacks of pancreatitis with symptom-free intervals.
In summary, we have demonstrated that mutations associ-
ated with hereditary pancreatitis alter CTRC-dependent pro-
teolytic regulation of human cationic trypsinogen and result in
markedly increased autoactivation. The findings suggest that
targeted therapy for the management of pancreatitis risk
should focus on continuous long-term suppression of trypsin-
ogen autoactivation.
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